Tricida operates in the healthcare industry focusing on pharmaceutical business.
Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 19, 2022 | Post-IPO Debt | $125M | 1 |
Hercules Capital
|
— | Detail |
| Mar 2, 2018 | Debt Financing | $100M | 1 |
Hercules Capital
|
— | Detail |
| Nov 8, 2017 | Series D | $57.50M | 1 | — | — | Detail |
| Jul 25, 2016 | Series C | $55M | 1 | — | — | Detail |
| Mar 4, 2015 | Series B | $30M | 1 | — | — | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Hercules Capital
|
Yes | Post-IPO Debt |
|
|
— | Series D |